Sorafenib inhibited phosphorylation of VEGFRs and PDGFRs receptors, but did not affect phosphorylation of insulin receptors, IGF1R and the EGF family of receptors in thyroid carcinoma cells. This evidence concerns the gene EGF and thyroid gland carcinoma.